# Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer

> **NCT06486545** · NA · NOT_YET_RECRUITING · sponsor: **Hunan Cancer Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Advanced Gastric Cancer

## Interventions

- **DRUG:** Irinotecan Hydrochloride Liposome Injection；Paclitaxel For Injection (Albumin Bound)

## Key facts

- **NCT ID:** NCT06486545
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-25
- **Primary completion:** 2025-07-30
- **Final completion:** 2026-01-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06486545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06486545, "Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06486545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*